New hope for esophageal cancer: combining chemoradiation with immunotherapy

NCT ID NCT04821778

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is looking at the best way to treat esophageal cancer that cannot be removed by surgery. It will follow 2,000 patients who receive chemoradiotherapy (radiation plus chemotherapy) along with possible immunotherapy or targeted drugs. The goal is to see which combinations help people live longer and with fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Radiotherapy, platinum-based chemotherapy, paclitaxel-based chemotherapy, anti-PD-1/PD-L1 immunotherapy, 5-FU analog chemotherapy, nimotuzumab
What this could lead to: If successful, this study could identify the best combination of chemoradiotherapy, immunotherapy, and targeted drugs to improve survival for people with advanced esophageal cancer.
What could go wrong: This is an observational cohort study, not a randomized trial, so results may not prove which treatment is best. Side effects from combined treatments can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHEMORADIATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chemotherapy-induced toxicity esophageal cancer Esophageal Neoplasms gastroesophageal junction adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHEMORADIATION CHEMOTHERAPY EFFECT ESOPHAGOGASTRIC JUNCTION CANCER ESOPHAGUS CANCER IMMUNOTHERAPY TARGETED THERAPY

Contacts and locations

Locations

Department 4th of Radiation Oncology, Anyang Cancer Hospital
RECRUITING

Anyang, Henan, 455001, China
Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC)
RECRUITING

Beijing, 100021, China
Department of Radiation oncology, Jiangsu Cancer Hospital/Jiangsu Institute of Cancer Research/The affiliated Cancer Hospital of Nanjing Medical University
RECRUITING

Nanjing, Jiangsu, 210009, China
Department of Radiation oncology, Jiangsu Province Hospital/The First Affiliated Hospital with Nanjing Medical University
RECRUITING

Nanjing, Jiangsu, 210029, China
Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University
RECRUITING

Changsha, Hunan, 410031, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.